MedDeviceGuide — IVD & Medical Device Knowledge Base

In-depth analysis of Bayer's acquisition of Perfuse Therapeutics for up to $2.45 billion, marking its return to M&A after a 5-year drought. Covers the PER-001 intravitreal implant for glaucoma and diabetic retinopathy, deal structure, endothelin receptor antagonism mechanism, the growing drug-device combination product market, and what it means for ophthalmic medtech manufacturers and investors.

GE HealthCare announced a sweeping restructuring of its business segments and executive leadership team alongside Q1 2026 earnings that missed expectations. Facing $250M in inflationary cost increases driven by memory chips, oil, and freight, the company is raising prices and cutting its profit outlook. Covers the new Advanced Imaging Solutions segment, leadership changes, the inflation impact on medtech supply chains, and what device manufacturers should expect.

Sun Pharmaceutical Industries agreed to acquire Organon & Co. for $11.75 billion in the largest pharmaceutical deal of 2026 and India's largest overseas pharma acquisition. Covers deal structure, Organon's portfolio of women's health products (Nexplanon, NuvaRing) and biosimilars (Hadlima, Renflexis), the drug-device combination products involved, regulatory considerations for combination products, and what the deal means for the women's health and biosimilar device landscape.

In-depth analysis of Danaher's $9.9 billion acquisition of Masimo, the largest medtech deal of 2026. Covers deal structure, strategic rationale, regulatory and antitrust considerations, competitive landscape impact on patient monitoring, and what it means for device manufacturers, hospitals, and investors.

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

Detailed analysis of MedTech Europe's May 2026 position paper on the proposed MDR/IVDR revision. Covers breakthrough/orphan pathways, cybersecurity, AI integration, IVDR-specific concerns, and what manufacturers need to know about the coming legislative process.

On May 7, 2026, the EU Council and Parliament reached a provisional deal to simplify AI Act rules. This guide breaks down what changed, what the product safety exemption means for medical devices, the new compliance timelines for AI-enabled SaMD and IVDs, and what manufacturers must do now.

Breaking down the FDA's May 2026 one-day inspection pilot that uses AI (Elsa) to target low-risk facilities. Covers how facilities are selected, what to expect during a screening inspection, how it differs from standard inspections, and what medical device manufacturers must do to stay ready.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.

A complete guide to Commission Implementing Regulation (EU) 2026/977, published May 4, 2026, which sets uniform quality management and procedural requirements for Notified Bodies conducting conformity assessments under the MDR and IVDR. Covers maximum timelines, clock-stop rules, quotation transparency, re-certification procedures, and what manufacturers need to know.

A practical survival guide for IVD manufacturers facing the May 26, 2026 IVDR Class C transition deadline. Covers who must apply to a Notified Body, the September 2026 agreement deadline, conditions for extended market access through 2028, common pitfalls, and a step-by-step action plan.

A practical guide to the April 2026 MDCG updates affecting every EU medical device and IVD manufacturer. Covers MDCG 2021-24 Rev.1 classification guidance changes, EMDN v3/2026 code updates (MDCG 2026-1, 2026-2, 2026-3, MDCG 2021-12 Rev.2), the Borderline and Classification Manual Version 5, and what manufacturers must do to stay compliant.

Practical guide to building the critical-task matrix for auto-injector and pen-injector human factors validation — task identification from URRA, needle shield removal, site selection, dose confirmation, hold time, misfire recovery, training decay, disposal, use-error root cause analysis, and FDA/IEC 62366 evidence expectations.

How the EPA's 2026 proposed rollback of ethylene oxide emissions standards affects medical device manufacturers, sterilization facilities, and supply chains — the 2024 rule, proposed changes, compliance timelines, and alternative sterilization strategies.

Step-by-step playbook for responding to FDA Additional Information requests in eSTAR 510(k) and De Novo submissions — response table format, file naming, version control, section mapping, RTA vs substantive deficiencies, and traceability to original submission sections.

A field-by-field evidence matrix mapping MDR Annex II/III technical documentation, ISO 14971 risk management, PMS/PMCF, cybersecurity, data governance, human oversight, and QMS records to EU AI Act high-risk obligations — for manufacturers who must comply with both frameworks simultaneously.

A systematic playbook for diagnosing and resolving EUDAMED bulk upload validation errors — covering XSD schema failures, Basic UDI-DI/UDI-DI mismatches, EMDN code issues, certificate linkage errors, DTX error codes, NB confirmation bottlenecks, and a pre-upload validation checklist.

A methodical approach to mining FDA's AI-enabled device list and 510(k) database for predicate devices — covering technological characteristic extraction, public summary limitations, weak predicate argument avoidance, and a complete predicate evaluation matrix.

Step-by-step guide to building the ASCA evidence package for 510(k) and De Novo submissions — ASCA Summary Test Report, declaration of conformity, lab accreditation status check, scope matching, withdrawn/suspended lab risk, FDA questions, and submission rescue strategies.

How to build the Unresolved Software Anomalies table for FDA premarket cybersecurity submissions — CVSS scoring, exploitability assessment, clinical impact analysis, compensating controls, SBOM linkage, VEX status, labeling language, release criteria, and common reviewer objections.